Major bottlenecks in HIV vaccine development: the light at the end of the tunnel

7 October 2013, 10:30 – 13:30
Room 129, International Convention Center (CCIB)

Host Institutions: European Commission + Universite Pierre et Marie Curie (FR)

Session Overview: Despite significant investments and global research efforts over the last 25 years, an effective HIV vaccine is currently not in sight. This and major failures in recent phase II and III clinical trials should lead to fundamental questioning of current models and development paradigms. HIV vaccine research has always been a priority in the European Union's activities and it has been supported throughout the Framework Programmes for Research and Innovation (FP) as well as through the European and Developing Countries Clinical Trials Partnership (EDCTP), which supports capacity building and advance clinical trials for HIV, TB and malaria in sub-Saharan Africa. Aspects of HIV vaccine design will be examined in the light of the questions above.

AGENDA

CHAIRS: Ruxandra Draghia-Akli (EC/Belgium), David Weiner (University of Pennsylvania/USA)

SPEAKERS:
1. Susan Barnett (Novartis/USA):
   Efforts invested in the past vaccine design research: lesson learned (10’)

2. David J. Lewis (Surrey Clinical Research Center/UK)
   Novel candidates in phase I targeting GP41 (10’)

3. Behazine Combadiere (INSERM/FR)
   Different route of administration in HIV vaccine design (10’)

4. Gabriella Scarlatti (San Raffaele Scientific Institute/IT)
   Experience of the NeutNet platform: detection of HIV neutralisation and beyond (10’)

5. Christian Brander (IRSICAIXA/ES)
   HIVACAT programme: a joint private and public sector-funded consortium dedicated to AIDS vaccine research and development (10’)

6. Patrice Debré (UPMC/FR)
A new vaccine strategy to both neutralize HIV and inhibit CD4 cells depletion (10')

PANELIST: Nina Russell (BMGF/USA)
OPEN DISCUSSION